Company Insights

ANNX supplier relationships

Explore interactive graphBrowse insights index
ANNX supplier relationship map

Annexon (ANNX): supplier relationships, underwriting partners and operational constraints investors need to know

Annexon is a clinical-stage biotech that discovers and develops complement-targeting therapies for autoimmune and neurodegenerative diseases. The company has no product revenue and monetizes through equity markets and milestone-driven financing, while its R&D and eventual commercialization depend on third‑party manufacturers, CROs and investor relations services. Recent disclosed activity shows Annexon raising capital through underwritten public offerings and outsourcing core manufacturing and clinical services—an operating model that trades fixed capital intensity for supply‑chain and execution risk. For primary research and deal diligence, visit https://nullexposure.com/.

Why Annexon outsources and how that shapes financial exposure

Annexon intentionally does not own manufacturing infrastructure; instead it contracts manufacturing and clinical services, keeping capital expenditure low while accepting supplier dependency. The company’s balance sheet reflects that posture: negative EBITDA, no revenue TTM and reliance on equity issuance to fund operations (company filings through FY2025–FY2026). That contracting posture produces a mix of long‑term commitments (office/lab lease through 2031 with an extension option) and modular work‑order relationships (MSAs and CRO work orders) that govern production and trials.

Key operating signals:

  • Contracting posture: Annexon runs a hybrid model—long-term real estate commitment in Brisbane coupled with framework MSAs and work orders for manufacturing and trials. Evidence for the mix comes from their lease disclosures and descriptions of Master Services/Quality agreements in public filings.
  • Concentration & criticality: Suppliers are material and critical to development and regulatory timelines; Annexon explicitly warns that supplier failure would materially impair the business.
  • Maturity & stage: Supplier relationships are largely active for clinical development, but Annexon has not engaged commercial-scale manufacturers yet, signaling a transition risk if a therapy progresses to approval.
  • Geographic footprint: Clinical programs run globally, including APAC trial sites in Bangladesh and the Philippines and data flows from EMEA to the U.S., increasing regulatory and logistics complexity.

If you want ongoing supplier monitoring and relationship maps for Annexon, see https://nullexposure.com/.

Who Annexon is working with today — every named relationship in the record

Below are the specific counterparties referenced in recent public notices and filings, with concise takeaways and source citations.

Goldman Sachs & Co. LLC / Goldman Sachs

Goldman Sachs served as a joint book‑running manager on Annexon’s public offering of common stock and pre‑funded warrants announced in November 2025 and reflected in subsequent pricing and closing notices. See the company press release (GlobeNewswire, Nov 12–13, 2025) and the pricing announcement carried by Yahoo Finance/market wires.

Source: Annexon press releases and offering notices (GlobeNewswire, Nov 2025; consolidated reporting on finance.yahoo.com).

TD Cowen

TD Cowen acted as a joint book‑running manager alongside Goldman Sachs and Wells Fargo on the same public offering and closing transactions, indicating the firm’s placement in Annexon’s capital markets syndicate for FY2025 activity.

Source: Company offering announcements shared on Quantisnow and Yahoo Finance (Nov 2025 / reporting captured in 2026 news aggregation).

Wells Fargo Securities / Wells Fargo

Wells Fargo Securities is listed as a joint book‑running manager on the offering and closing documents, reinforcing that Annexon used a multi‑bank syndicate to execute equity raises in late FY2025 and early FY2026.

Source: GlobeNewswire press releases and market coverage (Nov 2025; reproduced in StockTitan and Yahoo Finance summaries).

Broadridge Financial Solutions

Broadridge is referenced in offering documentation as the transfer/fulfillment contact for manual requests and shareholder communications during the offering process, indicating Broadridge’s role in investor communications and distribution logistics.

Source: Offering notice (GlobeNewswire, Nov 2025) that lists Broadridge contact points for TD Securities/transfer agent functions.

Fidelity Brokerage Services LLC

Fidelity is named in a SEC filing as the broker/holder tied to restricted stock vesting and compensation transactions, showing Fidelity’s role on the custodial and retail brokerage side of insider and employee share movements.

Source: SEC filing coverage reproduced on StockTitan (SEC filing referenced in FY2026 disclosures).

LifeSci Advisors

LifeSci Advisors is listed as Annexon’s investor relations contact on multiple press releases (including regulatory submissions and conference participation announcements), positioning LifeSci as the company’s retained IR and communications adviser during FY2025–FY2026.

Source: Company press releases (GlobeNewswire, Jan–Feb 2026; conference notice Feb 2026) naming LifeSci Advisors for investor contacts.

What the constraints tell investors about supply‑chain risk and contract exposure

Annexon’s constraints and disclosures deliver a consistent message: outsourced manufacturing and third‑party services are core to execution and are treated as materially important. The company’s lease in Brisbane runs through October 2031 with an extension option, which anchors a long‑term physical footprint even while production is outsourced under shorter work orders. Annexon cites Master Services Agreements and work orders governing timelines, volumes and quality, which implies framework contracting with specific task orders rather than discrete spot purchases.

Operational implications:

  • Procurement model: Framework MSAs + work orders for development and clinical supplies provide agility on scope but create dependency on vendor performance and cGMP compliance. The company acknowledges it does not plan to build internal manufacturing capability.
  • Spend intensity: Contract manufacturing is a significant line item in direct expenses (contract manufacturing figures are disclosed in financials), consistent with a spend band in the mid‑double‑digit millions for clinical manufacturing.
  • Global execution risk: Active trial sites across APAC and transfer of EMEA personal data to the U.S. raise regulatory complexity for both trials and data governance.

Investor takeaways and a short risk checklist

  • Capital markets reliance: Annexon funds operations through equity issuance—recent underwritten offerings (Nov 2025) were led by Goldman Sachs, TD Cowen and Wells Fargo Securities, confirming active capital‑markets support but also dilution risk. (GlobeNewswire, Nov 2025.)
  • Supplier concentration is systemic: Third‑party manufacturers and CROs are critical and labeled by the company as material; losing a supplier would adversely affect timelines and approvals.
  • Operational flexibility vs. execution risk: Framework contracts and cancelable agreements give Annexon negotiating flexibility, but the firm’s lack of internal manufacturing increases operational vulnerability if suppliers fail regulatory inspections or capacity constraints emerge.
  • Communications and custody: Broadridge and Fidelity cover distribution and broker custody functions, while LifeSci handles investor relations—an ecosystem that supports capital raises and shareholder communications but also channels material information flow.

If you want a one‑page relationship map and supplier risk scoring for Annexon, request it at https://nullexposure.com/.

Final verdict for investors

Annexon’s model is clear: science‑first R&D funded by equity markets and executed via outsourced manufacturing and clinical service providers. That model preserves capital but transfers execution risk to suppliers and CROs that the company itself calls critical. For investors, the primary diligence focus should be supplier quality controls, contingency plans for commercial supply, and the cadence of future financing events that fund late‑stage programs. For ongoing monitoring and alerts on supplier changes or new financings, visit https://nullexposure.com/ and request Annexon coverage.